{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-048997","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.936872+00:00","generated_at":"2026-05-15T04:09:19.054765+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Armata appoints Dr. Daniel Gilmer to Board; option award for 51,280 shares","bullets":["Dr. Daniel Gilmer (39) appointed to Board effective April 24, 2026.","He will receive an option award to purchase 51,280 shares vesting over three years.","Non-management directors receive a cash retainer of $40,000 per year.","Gilmer is Senior Director at Pfizer and led the U.S. launch of PAXLOVID.","He is co-inventor of Streptococcus phage lysin exebacase (CF-301)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-048997","json":"https://secwatch.observer/filing/0001104659-26-048997.json","markdown":"https://secwatch.observer/filing/0001104659-26-048997.md","text":"https://secwatch.observer/filing/0001104659-26-048997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926048997/0001104659-26-048997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926048997/tm2610924d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:09:19.054765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}